Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV, and BRSV in experimentally infected calves

Peters, A. R.; Thevasagayam, S. J.; Wiseman, Anat; Salt, Jeremy

doi:10.1016/j.prevetmed.2004.08.001

Cited by 34 publications

(40 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,8 When a proper management practice is implemented, vaccination can be an e®ective tool for preventing and controlling infectious diseases. 4 A commercially available multivalent 5-in-1 vaccine (BR, PI3, BRSV and BVD types I and II) was developed overseas. However, the vaccine is not imported due to the regulation in Taiwan.…”

Section: Discussionmentioning

confidence: 99%

Case Report: A Disease Outbreak of Bovine Respiratory Syncytial Virus in Taiwan

et al. 2014

View full text Add to dashboard Cite

A dairy farm with 300 Holstein cattle in Hsin-Chu County, Taiwan, had an outbreak of a respiratory disease from the end of September to November, 2013. Adult animals (1-5-yearold) showed clinical symptoms of anorexia, depression, fever, and dropped milk production during the early stage of infection. In severe cases, animals su®ered from dyspnea with frothy saliva at the edge of opened mouth. Samples were collected from eight sick animals, ampli¯ed in the baby hamster kidney cell-21 (BHK-21), and the cytopathic e®ect (CPE) was con¯rmed. Primers speci¯c to Bovine respiratory syncytial virus (BRSV), Bovine viral diarrhea virus (BVDV), Bovine herpesvirus type I (BHV-I), Bovine ephemeral fever virus (BEFV) and Mannheimia haemolytica were used to identify the pathogen responsible for this respiratory disease by polymerase chain reaction (PCR). Results of sequence analysis con¯rmed that BRSV is the causative pathogen for the respiratory infection. This is, to the best of our knowledge, the¯rst disease case of BRSV reported in Taiwan.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: A Disease Outbreak of Bovine Respiratory Syncytial Virus in Taiwan

et al. 2014

View full text Add to dashboard Cite

show abstract

“…For this reason BRSV vaccination-challenge studies reported in the literature were often either performed in older animals [19,20] or colostrum deprived calves [21]. or the challenge was performed later after vaccination [22,23], alternatively a combination of these different approaches was applied. However an early challenge of young calves with moderate to high maternally derived immunity, as described in this study, reflects the field situation.…”

Section: Discussionmentioning

confidence: 99%

A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody

Sluijs¹,

Kühn²,

Makoschey³

2010

BMC Vet Res

View full text Add to dashboard Cite

BackgroundThe efficacy of a single dose of an inactivated bovine respiratory syncytial virus (BRSV) - Parainfluenaza type 3 (PI3) - Mannheimia haemolytica (Mh) combination vaccine, in calves positive for maternal antibodies, was established in a BRSV infection study.ResultsAs expected the single vaccination did not have any effect on the decline of BRSV-specific neutralising or ELISA antibody. The cellular immune system was however primed by the vaccination. In the vaccinated group virus excretion with nasal discharge was reduced, less virus could be re-isolated from lung tissues and the lungs were less affected.ConclusionsThese results indicate that a single vaccination with an inactivated BRSV vaccine was able to break through the maternal immunity and induce partial protection in very young calves. It can be speculated that the level and duration of protection will improve after the second dose of vaccine is administered. A two-dose basic vaccination schedule is recommended under field conditions.

show abstract

“…Currently, there is little information regarding the duration of the protective response to bRSV after vaccination [48,49,87], as it is difficult to maintain cattle in isolation for prolonged periods. However, cattle can be experimentally reinfected as early as 35 days after initial infection with virulent bRSV even in the presence of circulating antibody [48,49,88].…”

Section: Duration Of Immunity To Natural Infection and Vaccinesmentioning

confidence: 99%

Immunization strategies for the prevention of pneumovirus infections

Bennett

Ellis

Bonville

et al. 2007

Expert Review of Vaccines

View full text Add to dashboard Cite

Pneumoviruses, which are viruses of the family Paramyxoviridae, subfamily Pneumovirinae, are pathogens that infect the respiratory tract of their host species. The human pneumovirus pathogen, human respiratory syncytial virus (RSV), has counterparts that infect cows (bovine RSV), sheep (ovine RSV), goats (caprine RSV) and rodents (pneumonia virus of mice). Each pneumovirus is host specific and results in a spectrum of disease, ranging from mild upper-respiratory illness to severe bronchiolitis and pneumonia with significant morbidity and mortality. Given the public health burden caused by human RSV and the concomitant agricultural impact of bovine RSV, these two viruses are considered as prime targets for the development of safe and effective vaccines. In this review, we describe the strategies used to develop vaccines against human and bovine RSV and introduce the pneumonia virus mouse model as a novel and invaluable tool for preclinical studies and new vaccine strategies.

show abstract

Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV, and BRSV in experimentally infected calves

Cited by 34 publications

References 13 publications

Case Report: A Disease Outbreak of Bovine Respiratory Syncytial Virus in Taiwan

Case Report: A Disease Outbreak of Bovine Respiratory Syncytial Virus in Taiwan

A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody

Immunization strategies for the prevention of pneumovirus infections

Contact Info

Product

Resources

About